Radha Bernander
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $56,490 of the $73,636 with a category attached, or 76.7%. Insulet Corporation accounts for 78.0% of it on its own, with 52 other manufacturers making up the rest. 2025 is the largest year on record at $33,447, more than ten times the $2,756 reported in 2021. Among medical clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 874 payments — averaging $84.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$57K
- AstraZeneca$2K
- Mannkind Corporation$2K
- Lilly USA, LLC$2K
- Dexcom, Inc.$1K
- Novo Nordisk$1K
- plus $8K from 47 others
What the payments were for
- Speaking & faculty fees$56,49077%
- Travel & lodging$3110%
- Food & beverage$16,80523%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$73,636 in reported general payments places this provider in the 95th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 129 | $186,122 |
| MounjaroTirzepatide | 86 | $106,537 |
| TrulicityDulaglutide | 58 | $102,590 |
| JardianceEmpagliflozin | 63 | $61,588 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 40 | $45,972 |
| FarxigaDapagliflozin Propanediol | 29 | $33,541 |
| TradjentaLinagliptin | 39 | $32,291 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $31,693 |
| Tresiba Flextouch U-100Insulin Degludec | 56 | $31,165 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 16 | $22,918 |
| RybelsusSemaglutide | 21 | $22,312 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $20,384 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $18,106 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $17,122 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 17 | $13,061 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,318 | $217,850178 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,676 | $214,601168 claims |
| Boehringer IngelheimJardiance, Tradjenta | $426 | $93,879102 claims |
| AstraZenecaFarxiga | $2,178 | $33,54129 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $405 | $17,12214 claims |
| AbbVieSynthroid | $435 | $5,76776 claims |
| IBSA Pharma Inc.Tirosint | $265 | $3,79812 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $64 | $2,585200 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,490 medical providers in Texas.
Other medical in Katy
- Chelsea BeiserKaty$18K
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Courtney AldridgeSan Antonio$89K
- Janine ShinnDallas$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.